Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2015

01-05-2015 | Review

Oncocers: ceRNA-mediated cross-talk by sponging miRNAs in oncogenic pathways

Authors: Sercan Ergun, Serdar Oztuzcu

Published in: Tumor Biology | Issue 5/2015

Login to get access

Abstract

Competing endogenous RNAs (ceRNAs) are RNA transcripts which can communicate with each other by decreasing targeting concentration of micro-RNA (miRNA) with the derepression of other messenger RNAs (mRNAs) having the common miRNA response elements (MREs). Oncocers are ceRNAs taking crucial roles in oncogenic pathways processed in many types of cancer, and this study analyzes oncocer-mediated cross-talk by sponging microRNAs (miRNAs) in these pathways. While doing this, breast, liver, colon, prostate, gastric, lung, endometrium, thyroid and epithelial cancers and melanoma, rhabdomyosarcoma, glioblastoma, acute promyelocytic leukemia, retinoblastoma, and neuroblastoma were analyzed with respect to ceRNA-based carcinogenesis. This study defines, firstly, oncocers in the literature and contains all oncocer-related findings found up to now. Therefore, it will help to increase our comprehension about oncocer-mediated mechanisms. Via this study, a novel perspective would be produced to make clear cancer mechanisms and suggest novel approaches to regulate ceRNA networks via miRNA competition for cancer therapeutics.
Literature
1.
2.
3.
4.
Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.CrossRefPubMed
5.
Tan J, Marques A. The miRNA-mediated cross-talk between transcripts provides a novel layer of posttranscriptional regulation. Adv Genet. 2013;85:149–99.
6.
Ergun S, Arman K, Temiz E, Bozgeyik İ, Yumrutaş Ö, et al. Expression patterns of miR-221 and its target caspase-3 in different cancer cell lines. Mol Biol Rep. 2014;41:5877–81.CrossRefPubMed
7.
Arman K, Ergün S, Temiz E, Öztuzcu S. The interrelationship between HER2 and CASP3/8 with apoptosis in different cancer cell lines. Mol Biol Rep. 2014;41(12):1–6.CrossRef
8.
Ergün S, Ulasli M, Igci Y, Igci M, Kırkbes S, et al. The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer. Mol Biol Rep. 2015;42:497–505.CrossRefPubMed
9.
Costa V, Esposito R, Aprile M, Ciccodicola A. Non-coding RNA and pseudogenes in neurodegenerative diseases:“the (un) usual suspects”. Front Genet. 2012;3:231.CrossRefPubMedPubMedCentral
10.
Ergün S, Öztuzcu S (2014) MiR-221: a critical player in apoptosis as a target of caspase-3. Cancer Cell Microenviron 1:10–14800/ccm. 14313.
11.
Sümbül AT, Göğebakan B, Ergün S, Yengil E, Batmacı CY, Yaldız M, Sezer A, Aldemir Ö, Özyılkan Ö. miR-204-5p expression in colorectal cancer: an autophagy-associated gene. Tumor Biol. 2014;35(12):12713–9.
12.
Ergun S, Oztuzcu S. Computational analysis of 3′ UTR Region of CASP3 with respect to miRSNPs and SNPs in targetting miRNAs. Comput Biol Chem. 2014;53PB:235–41.CrossRefPubMed
13.
14.
15.
16.
17.
18.
Ala U, Karreth FA, Bosia C, Pagnani A, Taulli R, et al. Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments. Proc Natl Acad Sci. 2013;110:7154–9.CrossRefPubMedPubMedCentral
19.
Kalyana-Sundaram S, Kumar-Sinha C, Shankar S, Robinson DR, Wu Y-M, et al. Expressed pseudogenes in the transcriptional landscape of human cancers. Cell. 2012;149:1622–34.CrossRefPubMedPubMedCentral
20.
Li L, Wang D, Xue M, Mi X, Liang Y, Wang P. 3′ UTR shortening identifies high-risk cancers with targeted dysregulation of the ceRNA network. Sci Rep. 2014;4:5406.
21.
22.
23.
24.
Karreth FA, Ala U, Provero P, Pandolfi PP (2014) Pseudogenes as competitive endogenous RNAs: target prediction and validation. Pseudogenes. Springer. pp. 199–212.
25.
26.
Yang J, Li T, Gao C, Lv X, Liu K, et al. FOXO1 3′ UTR functions as a ceRNA in repressing the metastases of breast cancer cells via regulating miRNA activity. FEBS Lett. 2014;588:3218–24.CrossRefPubMed
27.
Sen R, Ghosal S, Das S, Balti S, Chakrabarti J. Competing endogenous RNA: the key to posttranscriptional regulation. Sci World J. 2014;2014, 896206.CrossRef
28.
Giza DE, Vasilescu C, Calin GA. MicroRNAs and ceRNAs: therapeutic implications of RNA networks. Expert Opin Biol Ther. 2014;14:1285–93.CrossRefPubMed
29.
Su X, Xing J, Wang Z, Chen L, Cui M, et al. microRNAs and ceRNAs: RNA networks in pathogenesis of cancer. Chin J Cancer Res. 2013;25:235.PubMedPubMedCentral
30.
Karreth FA, Tay Y, Perna D, Ala U, Tan SM, et al. In vivo identification of tumor-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell. 2011;147:382–95.CrossRefPubMedPubMedCentral
31.
32.
Tay Y, Kats L, Salmena L, Weiss D, Tan SM, et al. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell. 2011;147:344–57.CrossRefPubMedPubMedCentral
33.
Sumazin P, Yang X, Chiu H-S, Chung W-J, Iyer A, et al. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell. 2011;147:370–81.CrossRefPubMedPubMedCentral
34.
Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 2011;147:358–69.CrossRefPubMedPubMedCentral
35.
Nie L, Wu H-J, Hsu J-M, Chang S-S, LaBaff AM, et al. Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer. Am J Transl Res. 2012;4:127.PubMedPubMedCentral
36.
de Giorgio A, Krell J, Harding V, Stebbing J, Castellano L. Emerging roles of competing endogenous RNAs in cancer: insights from the regulation of PTEN. Mol Cell Biol. 2013;33:3976–82.CrossRefPubMedPubMedCentral
37.
Zhou X, Liu J, Wang W. Construction and investigation of breast-cancer-specific ceRNA network based on the mRNA and miRNA expression data. IET Syst Biol. 2014;8(3):96–103.CrossRefPubMed
38.
Ferracin M, Bassi C, Pedriali M, Pagotto S, D’Abundo L, et al. miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression. Mol Cancer. 2013;12:130.CrossRefPubMedPubMedCentral
39.
Paci P, Colombo T, Farina L. Computational analysis identifies a sponge interaction network between long non-coding RNAs and messenger RNAs in human breast cancer. BMC Syst Biol. 2014;8:83.CrossRefPubMedPubMedCentral
40.
Hou P, Zhao Y, Li Z, Yao R, Ma M, et al. LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis. Cell Death Dis. 2014;5:e1287.CrossRefPubMedPubMedCentral
41.
Cha YH, Kim NH, Park C, Lee I, Kim HS, et al. MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. Cell Cycle. 2012;11:1273–81.CrossRefPubMed
42.
Fang L, Du WW, Yang X, Chen K, Ghanekar A, et al. Versican 3′-untranslated region (3′-UTR) functions as a ceRNA in inducing the development of hepatocellular carcinoma by regulating miRNA activity. FASEB J. 2013;27:907–19.CrossRefPubMed
43.
Zhao L, Li F, Taylor EW. Can tobacco use promote HCV-induced miR-122 hijacking and hepatocarcinogenesis? Med Hypotheses. 2013;80:131–3.CrossRefPubMed
44.
Pilyugin M, Irminger-Finger I. Long non-coding RNA and microRNAs might act in regulating the expression of BARD1 mRNAs. Int J Biochem Cell Biol. 2014;54:356–67.CrossRefPubMed
45.
Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, et al. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature. 2010;465:1033–8.CrossRefPubMedPubMedCentral
46.
Shen K, Mao R, Ma L, Li Y, Qiu Y, et al. Post‐transcriptional regulation of the tumor suppressor miR‐139‐5p and a network of miR‐139‐5p‐mediated mRNA interactions in colorectal cancer. FEBS J. 2014;281:3609–24.CrossRefPubMed
47.
Gao X, Fu C, Lao X, Tan Z. Competing endogenous RNA regulation mechanism and its role in the development and progression of colorectal cancer. Chin J Gastrointest Surg. 2012;15:1318–21.
48.
49.
Liu X-h, Sun M, Nie F-q, Ge Y-b, Zhang E-b, et al. lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol Cancer. 2014;13:92.CrossRefPubMedPubMedCentral
50.
51.
52.
Kumar MS, Armenteros-Monterroso E, East P, Chakravorty P, Matthews N, et al. HMGA2 functions as a competing endogenous RNA to promote lung cancer progression. Nature. 2014;505(7482):212–7.CrossRefPubMed
53.
Sacco J, Yau T, Darling S, Patel V, Liu H, et al. The deubiquitylase ataxin-3 restricts PTEN transcription in lung cancer cells. Oncogene. 2014;33(33):4265–72.CrossRefPubMed
54.
Zhou X, Gao Q, Wang J, Zhang X, Liu K, et al. Linc-RNA-RoR acts as a “sponge” against mediation of the differentiation of endometrial cancer stem cells by microRNA-145. Gynecol Oncol. 2014;133:333–9.CrossRefPubMed
55.
Kovalenko T, Sorokina A, Ozolinya L, Patrushev L. Methylation of the pseudogene PTENP1 5′-terminal region in endometrial cancer and hyperplasia. Russ J Bioorg Chem. 2013;39:397–405.CrossRef
56.
Fan M, Li X, Jiang W, Huang Y, Li J, et al. A long non-coding RNA, PTCSC3, as a tumor suppressor and a target of miRNAs in thyroid cancer cells. Exp Ther Med. 2013;5:1143–6.PubMedPubMedCentral
Metadata
Title
Oncocers: ceRNA-mediated cross-talk by sponging miRNAs in oncogenic pathways
Authors
Sercan Ergun
Serdar Oztuzcu
Publication date
01-05-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3346-x

Other articles of this Issue 5/2015

Tumor Biology 5/2015 Go to the issue

Research Article

The circadian gene CRY2 is associated with breast cancer aggressiveness possibly via epigenomic modifications

Research Article

The 7th AJCC/UICC TNM staging system may be not suitable in predicting prognosis of synchronous multiple gastric carcinoma patients with D2 gastrectomy

Research Article

Combined methylation of p16 and hMLH1 (CMETH2) discriminates a subpopulation with better prognosis in colorectal cancer patients with microsatellite instability tumors

Research Article

LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo

Research Article

microRNA-377 suppresses the proliferation of human osteosarcoma MG-63 cells by targeting CDK6

Research Article

Long noncoding RNA MALAT1 associates with the malignant status and poor prognosis in glioma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits